

Current Advancements in Stem Cell Technologies and their Potential for Tissue Engineering, Regenerative Medicine, and Organ Transplantation

Charan Sai Lanka

Abstract: *This review presents the stem cell technologies applied in tissue engineering, regenerative medicine, or organ transplantation. It describes how certain types of stem cells are different in terms of their characteristics, the methods of their culture isolation, gene editing, and three-dimensional organoid construction. We review the progress in Tissue engineering, Regenerative medicine, and organ transplantation in treating neurological, cardiovascular, diabetes, and musculoskeletal disorders. Furthermore, the limitations in developing stem cell technologies are also discussed in this review. The review gives closure to the potential role of stem cell technology in clinical practice.*

Keywords: Stem cells; Tissue engineering; Regenerative medicine; Induced pluripotent stem cells; Organoids; Bioprinting; Organ transplantation

1. Introduction

As the population increases with average life expectancy, degenerative diseases and injuries associated with age grow bigger. This marked an era of research with stem cells, which hold great promise for treating various diseases and is indeed one of the most fascinating and new frontiers of medicine, with endless potential. The mid-1960s revolutionized the field of stem cells when researchers McCulloch and James Till identified cells capable of self-renewal from mouse bone marrow. (1) This pioneering discovery provided new medical possibilities, thereby laying the foundation for future research on stem cells.

Stem cells originating in the zygote, can undergo unlimited cell division and produce cells with specific functions. Stem cells can differentiate into Mesenchymal, embryonic, and induced pluripotent stem cell types and can self-renew (Figure 1). Stem cells are recognized as one of the most essential elements of contemporary medicine. (2,3) Stem cells are ideal candidates for resolving various complex medical

problems, such as: restoring damage to whole organs, slowing the degenerative processes in the central nervous system, for example, Parkinson's and Alzheimer's diseases, developing different approaches in contrast to aggressive treatments, and understanding diseases from cellular level. (4)

According to available literature, stem cells enhance tissue regeneration. Mesenchymal, embryonic, and induced pluripotent stem cells, among others, have also been useful in regenerating damaged tissues. (5) Though stem cell therapy holds enormous potential for tissue regeneration, its clinical application is limited by factors such as poor survival rate and poor proliferation potential of the cells. As a solution, tissue engineering has been developed to increase stem cell viability and proliferation. This includes combining cells with biomaterials, biochemical and physicochemical factors, and engineering processes to restore or replace biological tissues. This paper presents an overview of stem cell types, including their uses and their contribution to tissue formation in an engineered context. In this review, however, we will limit ourselves to the above categories of stem cells. (4)

Mesenchymal stem cells (MSCs)	Embryonic stem cells (ESCs)	Induced Pluripotent Stem cells (iPSCs)
- These are fibroblast-like cells found in tissues like adipose tissue, tonsils, and bone marrow. - MSCs have gained recognition for their therapeutic effects, including inflammation suppression, regenerative responses, and angiogenesis. - They exhibit self-renewal and can form various tissues like fat, muscle, cartilage, and bone.	- These are pluripotent stem cells derived from the blastocyst, an early-stage pre-implantation embryo. - ESCs are being studied for clinical therapies, genetic disorders models, and cellular/DNA repair. - Researchers are focusing on the therapeutic potential of ESCs, including treating diabetes and heart disease.	- These are adult cells that have been reprogrammed back to a pluripotent state, offering a middle ground between embryonic stem cells and adult stem cells. - Recent developments in iPSC technology include enhanced reprogramming efficiency, non-integration reprogramming technologies, and diverse cell-type iPSCs. - These cells are suitable for autologous cell transplantation and can lower immunological rejection. iPSC-derived therapy for an age-related eye disease was first achieved at the RIKEN Institute in Japan. ((Seong Gyu Kwon et al))

Figure 1: Differentiation of types of Stem Cells

Considering stem cells' proliferative and differentiation abilities, researchers have produced new methods of reconstructing intricate organs such as bone, cartilage, and cardiac muscles. These developments have resulted in the invention of new tissue-engineered constructs suitable for implantation and the restoration of organ functionality. Recent studies have focused on the use of stem cell

technologies in regenerative medicine. Stem cells can differentiate into multiple cell lineages, including neurons, cardiac myocytes, and hepatocytes. Accordingly, they are considered to possess the ability to treat various disorders, from spinal cord injury to neurodegenerative diseases and organ failure. (4,6) Research focusing on stem cells in

regenerative medicine has had positive outcomes, hence the ongoing clinical trials.

Transplantation of organs stands out as one of the key remaining therapies to employ for patients who have reached a level of organ failure. Stem cell technologies can potentially address challenges in this area such as the organ shortage supply by providing other sources of transplantable organs. In the area under research, scholars focus on developing bioengineered organs based on stem cell-derived tissues, as well as the use of stem cells for enhancing the regeneration and repair processes of damaged organs. (4) This line of research has involved the creation of an organ constructed from bioengineered stem cell tissues to heal and regenerate the injured organs. (7)

One of the principal areas of research has been the application of stem cells in regenerative medicine, namely improved stem cell technology. Conditions including spinal cord injury, degenerative disorders, and organ failure, can be treated with Stem cells as they may develop into numerous types of cells, including neurons, cardiomyocytes, and hepatocytes. (4,6) Atala et al., were able to implant engineered bladders into patients, demonstrating the potential of tissue engineering. Their study includes culturing bladder cells from patient-provided cultures onto a collagen matrix. (8) Chong et al., showed that hESC-derived cardiomyocytes engrafted and enhanced cardiac function in hMPIs with myocardial infarction. Their work revealed crucial pre-clinical data that are relevant for heart repair using stem cells. (9) Mandai et al., published the first clinical study using iPSC-derived retinal cells to treat age-related macular degeneration. This work represents an important leap in regenerative medicine. (10)

Lancaster et al., devised a technique for generating brain organoids from human stem cells, a new substrate for exploring human-centric brain biology and pathologies. (11) Takebe et al., also reported the successful generation of human liver tissue from iPSCs, thus demonstrating the relevance of organoid technology towards organ regeneration and drug evaluation. (12) Gene editing with CRISPR-Cas9 has made numerous advancements in stem cell studies. In this case – Ma et al., were able to modify a hematopoietic cell by targeting with CRISPR-Cas9 in human embryos and creating plasmids for eliminating diseases at the time of origin of the embryo. (13)

The progress of current innovations in stem cell technologies brings us closer to the next medical revolution. This review focuses on the progress and applications of stem cell technology, including its application in organ transplants, tissue engineering, and regenerative medicine, along with existing challenges and future directions in this dynamic field.

2. Research Methodology

This section provides information on how the literature reviews current advancements in stem cell technology and the possibilities of their use for tissue engineering, regenerative medicine, and organ transplantation was conducted comprehensively. This paper describes the recently accomplished inventions and the research ongoing and

highlights possible discoveries. We conducted the literature search using PubMed, Google Scholar, and Scopus databases. The search combined two strategies, one based on the use of keywords such as "stem cells", "Tissue engineering", "regenerative medicine", "Organ transplantation" and others. These terms were combined with 'AND/OR' to form different sentence combinations.

Original research publications, review papers, systematic reviews, meta-analyses, and editorials were included. We considered articles published in peer-reviewed journals in English-language. We specifically prioritized papers focused on advancements and achievements related to stem cell applications. Opinions, abstracts, and conference papers were not included. Additionally, we excluded research using animal models with no clear human significance.

3. Results and Discussions

3.1 Applications in Stem Cell Technology Research

The field of stem cell research has experienced rapid growth and numerous breakthroughs in recent years. This section highlights some of the most significant advancements that have expanded our understanding and the potential applications of stem cell technologies.

1) Stem Cell Isolation and Culture

Improvements in isolation and culture methods have led to an exponential growth in the quality and number of stem cells measured in research and therapeutic applications. Recently, there has been a growing trend toward using Xeno-free and chemically defined culture systems that eliminate animal-derived components and variability in stem cell cultures. Cho et al., developed a completely defined Xeno-free medium for the long-term culture of hPSCs. (14) Such innovations enhance the sterility and consistency of stem cell cultures destined for therapeutic use. Three-dimensional structures and assemblies have developed as computational systems for studying the behavior of stem cells in their natural environments. Simian and Bissell et al., reviewed the relevance of 3D culture in preserving stem cells and differentiation processes. (15) Such systems enhance the physiological environment required to study stem cell functions and to engineer tissue constructs.

2) Gene Editing

Gene editing technologies, especially CRISPR-Cas9, have influenced stem cell studies and broadened the scope of disease modeling and therapy. With the help of CRISPR-Cas9, researchers have been able to produce better disease models using stem cells. For example, Freedman et al., developed mutant kidney organoids that had polycystic kidney disease mutations using CRISPR-Cas9, thus elucidating some aspects of disease progression. (16) In multiple studies gene editing on stem cells to rectify the encapsulated genetic errors has been achieved. Wu et al., and their colleagues were able to perform the first successful CRISPR-Cas9 insertion into iPSCs from a sickle cell patient, thereby paving the way for autologous cellular therapies in sickle cell patients. (17)

3.2 Re-programming Induced Pluripotent Stem Cells (iPSCs)

The methods used for generating induced pluripotent stem cells (iPSCs) have significantly improved since their initial development. To address the safety concerns associated with viral integration, many researchers have proposed non-integrating techniques for iPSC generation. Research by Inagaki et al., highlighted the most exciting advancements in the field of mRNA-based reprogramming, which offers a safer alternative compared to viral vectors. (18) Recent progress in direct reprogramming technologies now allows for transdifferentiating, which is the process of converting one cell type directly into another without passing through a pluripotent stage. Notably, Xu et al., successfully transformed fibroblasts into functional neurons, suggesting promising possibilities for cell-based therapies in treating neurological disorders. (19)

3.3 Organoids

Organoids are three-dimensional cellular aggregates that can replicate the fundamental structure and function of organs. Organoids are recognized widely as one of the most significant advancements in stem cell research. It is possible to generate organoids for many organ systems. Lancaster and Huch et al., have made significant contributions to the field of organoid technology by reviewing its usages in modeling development and disease. (20) There have been few advancements in organoid construction in tissue and organ studies because of the minimization of blood supply. Wimmer et al., successfully generated human brain organoids containing blood vessels, marking a crucial advance toward more complex and realistic organoid models. (21)

3.4 Single-Cell Technologies

The application of single-cell technologies has elevated the potential of stem cells to a new level of comprehension, allowing for a more detailed understanding of the heterogeneity and differentiation routes of stem cells. Wagner et al., demonstrated single-cell RNA sequencing as one technology for tracking the differentiation of hematopoietic stem cell lineages. (22) There has also been a study where matrices were synthesized to help lose spatial data, which offered micro-wells without dislodging the physical structure of a tissue. Furthermore, "slide – seq", which was studied by Rhodriques et al. in 2019, was able to provide a better understanding of stem-cell behavior in integrated tissues. (23) Significant advancements in stem-cell biology have expanded and deepened our understanding, enabling their application in clinical research.

4. Applications in Tissue Engineering

Tissue engineering is a broad field that integrates the principles of engineering and life sciences to design cell substitutes that can replace, improve, or restore the affected tissues.

4.1 Tissue Engineering Using Stem Cells

The principle behind tissue engineering is the combination of Growth factors, scaffolds, and cells to create functional tissue components. Stem cells are primary in this approach due to their acquisition of tissue regeneration and differentiation potential. In tissue engineering Mesenchymal stem cells (MSCs), Induced pluripotent stem cells (iPSCs), Embryonic stem cells (ESCs), and tissue-specific progenitor cells are employed. Each cell type has its own set of advantages and restrictions. For example, Pittenger et al., have examined the applicability of MSCs in regenerative medicine and differentiated them as such. (7) Scaffolds are important as they provide a surface and three-dimensional space for the cells to grow and form tissues. In recent years, advances in biomaterials have resulted in the emergence of bioactive scaffolds able to boost stem cell survival, proliferation, and differentiation. In a recent study, Selim et al., report the use of a 3D-printed scaffold controllably releasing growth factors that allowed stem cells to harness superior bone regeneration potential. (24) Growth factors and signaling molecules regulate the differentiation of stem cells and the subsequent formation of tissues. The delivery method of these substances often necessitates careful regulation within a specific tissue engineering framework. For instance, Wang et al., employed a hydrogel system for the controlled release of growth factors to improve the cardiac tissue engineering process using human iPSC-derived cardiomyocytes. (25)

4.2 Examples of Engineered Tissues

4.2.1 Bone

Bone tissue engineering has progressed, especially in the management of large skeletal defects. Mitra et al., reported that a perfusion bioreactor is a nit becomes the solution for large-scale harvesting of engineered bone grafts from large vascular nutrient vessels such as human MSCs, thus resolving the major problem of vascular supply in the bioreactor. (26)

4.2.2 Skin

Skin tissue engineering has reached an important level of development with hundreds of clinical products on the market today. Dehkordi et al., noted that recent advances in skin tissue engineering include the stem cells approach whose specific aim is to improve the wound healing process and scarring minimization. (27) One case in point here is the publication by Hirsch et al., where patients with junctional epidermolysis bullosa were treated with their own epidermal stem cells Research on stem cell transplantation for genetic skin diseases. (28)

4.2.3 Cartilage

Due to its low potential for self-regeneration, cartilage is one of the most important tissues for bioengineering. Diederichs et al., have reported the creation of hyaline cartilage tissues from human iPSCs which in the future may be implanted in patients instead of the damaged cartilage. (29) This would enhance potential management strategies for individuals with damage to the cartilage.

4.2.4 Cardiac Tissue

Engineering actual functional cardiac tissue continues to be difficult due to the intricate functional complexity of the heart

organ. Progress has however been recorded with the use of stem cell-derived cardiomyocytes. Ronaldson-Bouchard et al., reported making human cardiac tissues, which were like adult human tissues, using stem cell (specifically, iPSC) derived cardiomyocytes through a Bio-wire platform and electrostimulation. (30) Endocardial tissues engineered with this method matured to resemble structural and functional characteristics of adult myocardium.

4.2.6 Neural Tissue

Neural tissue engineering is also an avenue that can be explored in the management of neurological diseases and injuries. Joung et al., looked at the use of human iPSC-derived neural progenitor cells for spinal cord regeneration in a spinal cord-injured rat model with a 3D-printed scaffold. (31) This study depicted significant functional recovery of the subjects further implying the feasibility of stem cell-based approaches in the field of neural engineering.

Bone	Mitra et al., proposed a perfusion bioreactor for large-scale harvesting of engineered bone grafts from human MSCs, addressing the issue of vascular supply in the bioreactor.
Skin	Recent skin tissue engineering advancements, including stem cell transplantation, aim to enhance wound healing and scarring reduction. A study by Hirsch et al., demonstrated the potential of stem cell transplantation for treating genetic skin diseases.
Cartilage	Diederichs et al., developed hyaline cartilage tissues from human iPSCs, which could be implanted in patients to improve management strategies for cartilage damage.
Cardiac Tissue	. Ronaldson-Bouchard et al., created human cardiac tissues using iPSC-derived cardiomyocytes via a Bio-wire platform and electrostimulation, resulting in endocardial tissues resembling adult myocardium characteristics.
Neural Tissue	Joung et al., utilized human iPSC-derived neural progenitor cells for spinal cord regeneration in a rat model, demonstrating significant functional recovery, and highlighting the feasibility of stem cell-based neural engineering approaches.

Figure 2: Recent Innovations of Engineered Tissues

As the field progresses, integrating stem cell technologies with tissue engineering principles shows great potential for creating functional tissue replacements and innovative therapeutic strategies (Figure 2).

5. Applications in Regenerative Medicine

Regenerative medicine focuses on “regenerating” human cells, tissues, or organs with the intent of restoring or establishing normal functions. This branch is focused on tissue and organ replacement through stem cells as they possess the ability to self-renew and differentiate. The current section extends the discussion by showcasing several areas where stem cell technologies have been integrated within regenerative medicine.

5.1 Stem Cell Therapies for Various Diseases

Stem cell-based therapies are helpful in the treatment of a range of neurological, cardiovascular, diabetes, and musculoskeletal conditions that comprise (Figure 3):

5.1.1 Neurological Disorders

a) Parkinson's Disease:

Schweitzer et al., conducted a clinical trial using iPSC-derived dopaminergic progenitors for the treatment of Parkinson's Disease. (32) The study indicated the safety and effectiveness of this method as their patients were observed to have better motor function parameters.

b) Alzheimer's Disease:

Kim et al., reported the development of a 3D model of Alzheimer's disease by incorporating human neural stem cells. (33) Although targeting stem cells directly for therapy in Alzheimer's remains difficult – their 3D model provided

new insights into the mechanisms of the disease as well as potential approaches for treatment.

c) Spinal Cord Injury:

Nagoshi et al., published a comprehensive review on the advancement of stem cell therapy for spinal cord injury, confirming the significant role of neural stem or progenitor cells and neural cells from iPSCs in functional restoration. (34)

5.1.2 Cardiovascular diseases

a) Myocardial Infarction

Jiang Yu et al., conducted a meta-analysis of randomized controlled trials that made use of mesenchymal stem cells in the treatment of acute myocardial infarction. The authors noted some improvement in cardiac function parameters and a reduction in scar area. (35)

b) Heart Failure:

Fernández-Avilés et al., provided an overview of the current state of reviving therapies for patients suffering from heart failure, outlined the prospects of several stem cells, and the obstacles in the clinical application of these therapies.(36)

5.1.3 Diabetes

Stem cell-based approaches for diabetes focus on generating insulin-producing beta cells as reported by Velazco-Cruz et al., as they improved protocol for generating functional pancreatic β cells from human pluripotent stem cells, achieving glucose-responsive insulin secretion in vitro and after transplantation in mice. (37)

5.1.4 Orthopaedic Conditions

a) Osteoarthritis:

Mardones et al., conducted a trial on mesenchymal stem cells for osteoarthritis treatment, covering the use of intra-articular injections or tissue engineering techniques. (38)

b) Bone Defects:

Gómez-Barrena et al., described a multi-center clinical study aimed at evaluating the safety and efficacy of autologous mesenchymal stromal cells for surgery-free long bone non-union and suggested its safety with effectiveness. (39)




Figure 3: Recent advancements in Stem-cell-based therapies for treating multiple diseased conditions

5.2 Current Status of Treatments

The clinical evolution of therapies using stem cell research has made the following developments: The following few therapies targeting stem cells have been approved by the regulatory authorities:

- Alofisel cell therapy (Darvadstrocel):** It has received authorization in the European Union as a treatment for severe cases of perianal fistulas in Crohn's Disease patients. It uses stem cells derived from adipose tissue. (40)
- Strimvelis:** It is considered gene therapy done on an individual's specific cells with the use of CD34+ cells in patients with Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID). (41)

5.3 Challenges in Regenerative Medicine

Despite advancements, multiple barriers in the field of regenerative medicine have been faced (42):

- Potential adverse effects:** Administration of drug therapies with stem cell variants does require effective planning as it is highly likely that it would be dangerous for the health of the user, in particular for users who possess stem cells from multiple sources.
- Economical challenges:** An ideal clinical application should be affordable and capable of delivering stem cells meeting clinical standards for mass utilization.
- Cell engraftment and delivery:** Research is in progress for enhancing cell transplantation by increasing the

effectiveness of delivery methods as well as the long-term survival of the transplanted cells.

- Rejection of the transplanted tissue:** Controlling immune response against allogeneic stem cell therapy remains one of the major obstacles in therapy with allogeneic stem cells, targeting the immune system in transplantation and creating universal donor cells are such research in progress.

5.4 Prospects in Regenerative Medicine:

- Development of "off-the-shelf" allogeneic stem cell therapies for increased availability and affordability.
- Incorporation of gene editing techniques to improve stem cells and derive more effective cell lines that would be non-susceptible to diseases.
- Progression of in vivo reprogramming and trans-differentiation techniques that would aid in promoting native tissue regeneration.
- Investigating the possibilities of stem cells in conjunction with biomaterials, gene therapy, or therapeutic drugs to achieve combinational therapies.
- Creation of more complex disease models based on stem cell organoids to enhance drug discovery and targeted therapies.
- In light of the rapid development of the regenerative medicine field, stem cell technologies seem to have the potential to become a critical tool in creating innovative treatments for various diseases and even trauma. (43)

6. Advancements in Organ Transplantation

The scarcity of donor organs is a key issue the healthcare system faces today. Future solutions involving the bioengineering of cells, tissues, and organoids are possible. This section discusses some of the recent developments in bioengineering and their impact.

6.1 Creating Organoids and Mini-Organs

Organoids are 3D cell structures that have remarkably similar structures as well as functionalities of organs, although these have not been used in medical procedures yet, they are a huge stepping stone in gaining a deeper understanding of organ creation and defective development (*Figure 4*).

6.1.1 Kidney Organoids

Morizane et al., made mention of organoids which are derived from human pluripotent stem cells, these organoids can potentially serve enormous purposes including drug

screening, modeling, and regenerating medicine. Previous studies have also shown these organoids can serve some roles of kidneys as well including the production of urine. (44)

6.1.2 Liver Organoids

Sang et al., studied liver organoid technology and its applications. Some of the applications of such purpose would include examining healthy liver and liver-related diseases and toxicity testing for new drugs, but potential applications still require further research. Studies have indicated that recently improved ability and transformation of liver organoids have brought aid in targeted therapies since the organs are more functional. (45)

6.1.3 Heart Organoids

According to Lewis-Israeli et al., various methods can derive human heart organoids with distinct functional properties and tissue architectures. (46) These organoids have the potential to be useful in areas such as cardiac tissue engineering, organogenesis modeling, and even in regenerative medicine.




Figure 4: Organoids

6.2 Development of Organs using Stem Cell Bioprinting

With the use of stem cells and 3D bioprinting technology, it would be possible to formulate complex organ systems with appropriate spatial organization.

6.2.1 Current State of Bioprinting

Cui et al., analyzed the advancements made in 3D bioprinting techniques that aimed at creating bioartificial organs for tissue engineering and organ replacement purposes through various bioprinting techniques. (47) The processes that involve 3D printing of fully functional organs have, however, not been accomplished; rather, the structures have been developed to resemble organ tissue.

6.2.2 Vascularization Challenges

An interdisciplinary approach is needed to develop bio-printed vascular networks that supply nutrients, oxygen, and

regulators to organ cells. Jafarkhani et al., addressed this gap by presenting methods of achieving vascularization in 3D bio-printed tissues, where additional materials and factors are applied to influence the processes of 3D bioprinting. (48)

6.2.3 Bioink Development

More research in bio-ink formulations has enhanced the survival and function of the printed branched tissue. Concerning this, Chimene et al., gave an overview of recent work carried out in the formulation of advanced bioinks for printing tissues and organs, emphasizing biomimetic materials and hybrid bioinks. (49)

6.3 Xenotransplantation and Stem Cells

Xenotransplantation is the use of organs from another species which can reduce the available organ shortages, it is a practice

that can come to future use. Stem cell technologies are important in fostering progress in this type of transplantation.

6.3.1 Genetically Modified Pigs

According to Sykes and Sachs et al., there have been cases of xenotransplantation using genetically modified pig organs as transplant organs. (50) Through the combination of genetic engineering and stem cell technologies, it is possible to end up with pig organ tissue with a better chance of human implantation.

6.3.2 Humanized Animal Organs

Tan et al., have reported on human-monkey chimeric embryos using extended pluripotent stem cells which may pose some ethical concerns. (51) Nevertheless, this kind of research has potential in cross-species chimera formations with new techniques yielding implantable equivalent human organs by producing the organs through fusion.

6.4 Challenges in Organ Transplantation

Even though a lot of work has been accomplished, there is still, what needs to be pinpointed, several practical problems in the development of functional bioengineered organs (52) :

- a) **Transplantable Organ Sizing:** Formulating strategies that would facilitate the synthesis of organs to a dimension viable for human use.
- b) **Proper Development:** Achieving regulation of the functional development of variant tissues and organs that have been bioengineered.
- c) **Rejection:** Possible chances of rejection for transplanted tissues based on immunity.
- d) **Long-term Functionality:** Ability of bioengineered organs to survive and perform effectively in vivo for the desired period.

6.5 Prospects in Organ Transplantation

The science of bioengineered organs which can be transplanted is a booming area and a few directions that look promising include the following (53):

- a) **Multi-facet approaches:** Employing three-dimensional bioprinting, and organoid technologies along with structural and genetic engineering to fabricate larger and more advanced organ substitutes.
- b) **Organ engineering for individuals:** Taking specific iPSCs as per the patient for assimilation into bioengineered organs providing compatibility to the immune system.
- c) **Organ development in-vivo:** Developing organ or stem cell-directed factors in conjunction with in-situ conversion for future organ development.
- d) **Mini kidney chip repair techniques:** Developing micro-engineered/microfluidic technologies that would model kidney function for drug development and disease modeling and maybe sometimes reduce the need for kidney transplants.
- e) **AI and new computational techniques:** Creating innovative paradigms to facilitate a deeper understanding of organ performance and treatment personalization.

7. Challenges and Future Perspectives

Stem cell technologies have gained more popularity in the past few years and appear to have transcending potential for advancement in tissue engineering, organ transplantation, and regeneration. However, other challenges should be investigated before these technologies can be entirely implemented into the existing clinical approaches. This section encapsulates all the major challenges and outlines the future directions within the scope of this field especially concerning the clinical translation components.

7.1 Technical Challenges

- Maintaining standardization in the quality and safety of stem cell-derived products is challenging due to the current regulatory framework and quality challenges in the marketplace, highlighting the need for more rigorous characterization and potency tests, as highlighted by Volpato and Webber et al. (54)
- Addressing immunization in case of cell-based therapies using stem cells of different origins, Legal and ethical constraints on stem cell therapies.

7.2 Ethical Challenges

The ethical debate surrounding the use of stem cells, including human embryonic stem cells, and their derivatives, such as new cell therapies, has raised contemporary issues such as the right to self-determination, changes in business authority, and the generation of chimeras. (55)

7.3 Regulatory Challenges

The lack of coordinated legal and regulatory frameworks across countries for clinical stem cell-based therapies poses a significant challenge to clinical implementation. (56)

7.4 Future Directions and Potential Breakthroughs

Nevertheless, the amalgamation of stem cell research and its utilizations will progress further at an unprecedented pace and more innovations will come about. The most significant changes which are expected to impact this area are few, but significant:

7.4.1 Integration of Advanced Technologies

Due to Global inhibition, it is anticipated that iPSC and bioprinting will make technological and economic breakthroughs in reproductive biotechnology due to the prevalence of various biomaterial substitutes.

- **Artificial Intelligence and Machine Learning:** Issa et al., have analyzed publications on AI in stem cell research and see the power of AI for establishing optimal protocols for differentiating and other methods, predicting stem cell fate, and automating Stem Cell Quality Control processes. (57)
- **Single-Cell Multi-Omics:** These techniques reveal new information about stem cell diversity, lineage development, and determination at the cellular level. (58)
- **Gene Editing:** With the improvements seen in CRISPR technology and other means of editing genes, it has made it easier to change the genetic makeup of stem cells.

7.4.2 Novel Therapeutic Approaches

New techniques are increasing the range of stem cell technologies' uses:

- **In Vivo Reprogramming:** Srivastava et al., presented direct in vivo reprogramming aiming for tissue regeneration and its recent advances and potential to treat several disorders without cell transplantations. (59)
- **Extracellular Vesicles:** Putthanbut et al., highlighted the prospects of using extracellular vesicles derived from stem cells and other cells in tissue transplants including for restorative insecurity. (60)
- **Bioengineered Tissues for Drug Discovery:** Ramadan et al., explained how organoids and organ models obtained from stem cells are changing the landscape of drug development and drug targeting alongside tailored therapeutic measures. (61)

8. Limitations of the Study

- It is possible that some very recent developments may not be included.
- The focus on English-language publications may have excluded relevant studies published in other languages.
- The emphasis on human applications may have overlooked some important fundamental research in animal models.

9. Conclusion

Stem cells and their advancements in regenerative medicine, tissue engineering, and organ transplantation have significantly advanced over the last few years. Even though serious problems still exist, integrating stem cell biology with other high-end technologies provides infinite probabilities for the solutions to unfulfilled medicinal requirements. Moving forward, we need to see more ethical considerations, expert dealings with regulatory frameworks, and a more robust collaboration between disciplines to actualize the possible exploration of stem cell technologies. The promising development and removal of prior restrictions on stem cell methods are poised to usher in a transformative change in medical practice, particularly in treating conditions and injuries previously deemed incurable.

References

- [1] Till JE, McCulloch EA. A Direct Measurement of the Radiation Sensitivity of Normal Mouse Bone Marrow Cells. *Radiation Research*. 2012 Aug;178(2):AV3–7.
- [2] Weissman IL. Stem Cells. *Cell*. 2000 Jan;100(1):157–68.
- [3] Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic Stem Cell Lines Derived from Human Blastocysts. *Science*. 1998 Nov 6;282(5391):1145–7.
- [4] Kwon SG, Kwon YW, Lee TW, Park GT, Kim JH. Recent advances in stem cell therapeutics and tissue engineering strategies. *Biomater Res*. 2018 Dec 6;22(1):36.
- [5] Takahashi K, Yamanaka S. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. *Cell*. 2006 Aug;126(4):663–76.
- [6] Pandey D. Biotechnological Potential of Stem Cells. *JSRT* [Internet]. 2017 Jul 17 [cited 2024 Nov 20];3(1). Available from: <https://medcraveonline.com/JSRT/biotechnological-potential-of-stem-cells.html>
- [7] Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. *npj Regen Med*. 2019 Dec 2;4(1):22.
- [8] Atala A, Bauer SB, Soker S, Yoo JJ, Retik AB. Tissue-engineered autologous bladders for patients needing cystoplasty. *The Lancet*. 2006 Apr;367(9518):1241–6.
- [9] Chong JJH, Yang X, Don CW, Minami E, Liu YW, Weyers JJ, et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. *Nature*. 2014 Jun;510(7504):273–7.
- [10] Mandai M, Watanabe A, Kurimoto Y, Hiram Y, Morinaga C, Daimon T, et al. Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration. *N Engl J Med*. 2017 Mar 16;376(11):1038–46.
- [11] Lancaster MA, Renner M, Martin CA, Wenzel D, Bicknell LS, Hurler ME, et al. Cerebral organoids model human brain development and microcephaly. *Nature*. 2013 Sep 19;501(7467):373–9.
- [12] Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. *Nature*. 2013 Jul 25;499(7459):481–4.
- [13] Ma H, Marti-Gutierrez N, Park SW, Wu J, Lee Y, Suzuki K, et al. Correction of a pathogenic gene mutation in human embryos. *Nature*. 2017 Aug;548(7668):413–9.
- [14] Cho Y, Lee H, Jeong W, Jung KB, Lee SY, Park S, et al. Long-Term Culture of Human Pluripotent Stem Cells in Xeno-Free Condition Using Functional Polymer Films. *Advanced Materials*. 2024 Jul 17;2403952.
- [15] Simian M, Bissell MJ. Organoids: A historical perspective of thinking in three dimensions. *Journal of Cell Biology*. 2017 Jan 2;216(1):31–40.
- [16] Freedman BS, Brooks CR, Lam AQ, Fu H, Morizane R, Agrawal V, et al. Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids. *Nat Commun*. 2015 Oct 23;6(1):8715.
- [17] Wu Y, Zeng J, Roscoe BP, Liu P, Yao Q, Lazzarotto CR, et al. Highly efficient therapeutic gene editing of human hematopoietic stem cells. *Nat Med*. 2019 May;25(5):776–83.
- [18] Inagaki M. Cell Reprogramming and Differentiation Utilizing Messenger RNA for Regenerative Medicine. *JDB*. 2023 Dec 20;12(1):1.
- [19] Xu J, Du Y, Deng H. Direct Lineage Reprogramming: Strategies, Mechanisms, and Applications. *Cell Stem Cell*. 2015 Feb;16(2):119–34.
- [20] Lancaster MA, Huch M. Disease modelling in human organoids. *Disease Models & Mechanisms*. 2019 Jul 1;12(7):dmm039347.
- [21] Wimmer RA, Leopoldi A, Aichinger M, Wick N, Hantusch B, Novatchkova M, et al. Human blood vessel organoids as a model of diabetic vasculopathy. *Nature*. 2019 Jan;565(7740):505–10.

- [22] Wagner DE, Weinreb C, Collins ZM, Briggs JA, Megason SG, Klein AM. Single-cell mapping of gene expression landscapes and lineage in the zebrafish embryo. *Science*. 2018 Jun;360(6392):981–7.
- [23] Rodriques SG, Stickels RR, Goeva A, Martin CA, Murray E, Vanderburg CR, et al. Slide-seq: A scalable technology for measuring genome-wide expression at high spatial resolution. *Science*. 2019 Mar 29;363(6434):1463–7.
- [24] Selim M, Mousa HM, Abdel-Jaber GT, Barhoum A, Abdal-hay A. Innovative designs of 3D scaffolds for bone tissue regeneration: Understanding principles and addressing challenges. *European Polymer Journal*. 2024 Jul;215:113251.
- [25] Wang AY, Rafalko J, MacDonald M, Ming X, Kocharian R. Absorbable Hemostatic Aggregates. *ACS Biomater Sci Eng*. 2017 Dec 11;3(12):3675–86.
- [26] Mitra D, Whitehead J, Yasui OW, Leach JK. Bioreactor culture duration of engineered constructs influences bone formation by mesenchymal stem cells. *Biomaterials*. 2017 Nov;146:29–39.
- [27] Nourian Dehkordi A, Mirahmadi Babaheydari F, Chehelgerdi M, Raeisi Dehkordi S. Skin tissue engineering: wound healing based on stem-cell-based therapeutic strategies. *Stem Cell Res Ther*. 2019 Dec;10(1):111.
- [28] Hirsch T, Rothoeft T, Teig N, Bauer JW, Pellegrini G, De Rosa L, et al. Regeneration of the entire human epidermis using transgenic stem cells. *Nature*. 2017 Nov;551(7680):327–32.
- [29] Diederichs S, Klampfleuthner FAM, Moradi B, Richter W. Chondral Differentiation of Induced Pluripotent Stem Cells Without Progression Into the Endochondral Pathway. *Front Cell Dev Biol*. 2019 Nov 1; 7: 270.
- [30] Ronaldson-Bouchard K, Ma SP, Yeager K, Chen T, Song L, Sirabella D, et al. Advanced maturation of human cardiac tissue grown from pluripotent stem cells. *Nature*. 2018 Apr;556(7700):239–43.
- [31] Joung D, Truong V, Neitzke CC, Guo S, Walsh PJ, Monat JR, et al. 3D Printed Stem-Cell Derived Neural Progenitors Generate Spinal Cord Scaffolds. *Adv Funct Materials*. 2018 Sep;28(39):1801850.
- [32] Schweitzer JS, Song B, Herrington TM, Park TY, Lee N, Ko S, et al. Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease. *N Engl J Med*. 2020 May 14;382(20):1926–32.
- [33] Kim YH, Choi SH, D'Avanzo C, Hebisch M, Sliwinski C, Bylykbashi E, et al. A 3D human neural cell culture system for modeling Alzheimer's disease. *Nat Protoc*. 2015 Jul;10(7):985–1006.
- [34] Nagoshi N, Tsuji O, Nakamura M, Okano H. Cell therapy for spinal cord injury using induced pluripotent stem cells. *Regenerative Therapy*. 2019 Dec;11:75–80.
- [35] Yu J, Zhang R feng, Mao Y li, Zhang H. Efficacy and Safety of Mesenchymal Stem Cell Therapy in Patients with Acute Myocardial Infarction: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *CSCR*. 2022 Nov;17(8):793–807.
- [36] Fernández-Avilés F, Sanz-Ruiz R, Climent AM, Badimon L, Bolli R, Charron D, et al. Global position paper on cardiovascular regenerative medicine. *European Heart Journal*. 2017 Sep 1;38(33):2532–46.
- [37] Velazco-Cruz L, Song J, Maxwell KG, Goedegebuure MM, Augsornworawat P, Hogrebe NJ, et al. Acquisition of Dynamic Function in Human Stem Cell-Derived β Cells. *Stem Cell Reports*. 2019 Feb;12(2):351–65.
- [38] Mardones R, Jofré CM, Tobar L, Minguell JJ. Mesenchymal stem cell therapy in the treatment of hip osteoarthritis. *Journal of Hip Preservation Surgery*. 2017 Jul;4(2):159–63.
- [39] Gómez-Barrena E, Padilla-Eguiluz N, Rosset P, Gebhard F, Hernigou P, Baldini N, et al. Early efficacy evaluation of mesenchymal stromal cells (MSC) combined to biomaterials to treat long bone non-unions. *Injury*. 2020 Apr;51:S63–73.
- [40] Taxonera C, García-Brenes MA, Olivares D, López-García ON, Zapater R, Alba C. Darvadstrocel for complex perianal fistulas in Crohn's disease: A systematic review and meta-analysis. *UEG Journal*. 2024 Oct 3;ueg2.12673.
- [41] Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, et al. Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency. *N Engl J Med*. 2009 Jan 29;360(5):447–58.
- [42] Syed Muhammad Nazim, Sarfraz Ahmad. Stem cell research, regenerative medicine and challenges. *J Pak Med Assoc*. 2023 Jan 25;73(2):S143–7.
- [43] Altyar AE, El-Sayed A, Abdeen A, Piscopo M, Mousa SA, Najda A, et al. Future regenerative medicine developments and their therapeutic applications. *Biomedicine & Pharmacotherapy*. 2023 Feb;158:114131.
- [44] Morizane R, Lam AQ, Freedman BS, Kishi S, Valerius MT, Bonventre JV. Nephron organoids derived from human pluripotent stem cells model kidney development and injury. *Nat Biotechnol*. 2015 Nov;33(11):1193–200.
- [45] Sang C, Lin J, Ji S, Gao Q. Progress, application and challenges of liver organoids. *CCB*. 2024 Mar 25;3(1):7.
- [46] Lewis-Israeli YR, Wasserman AH, Gabalski MA, Volmert BD, Ming Y, Ball KA, et al. Self-assembling human heart organoids for the modeling of cardiac development and congenital heart disease. *Nat Commun*. 2021 Aug 26;12(1):5142.
- [47] Cui H, Nowicki M, Fisher JP, Zhang LG. 3D Bioprinting for Organ Regeneration. *Adv Healthcare Materials*. 2017 Jan;6(1):1601118.
- [48] Jafarkhani M, Salehi Z, Aidun A, Shokrgozar MA. Bioprinting in Vascularization Strategies. *Iran Biomed J*. 2019 Jan;23(1):9–20.
- [49] Chimene D, Kaunas R, Gaharwar AK. Hydrogel Bioink Reinforcement for Additive Manufacturing: A Focused Review of Emerging Strategies. *Advanced Materials*. 2020 Jan;32(1):1902026.
- [50] Sykes M, Sachs DH. Transplanting organs from pigs to humans. *Sci Immunol*. 2019 Nov;4(41):eaau6298.
- [51] Tan T, Wu J, Si C, Dai S, Zhang Y, Sun N, et al. Chimeric contribution of human extended pluripotent stem cells to monkey embryos ex vivo. *Cell*. 2021 Apr;184(8):2020-2032.e14.

- [52] Beyar R. Challenges in organ transplantation. *Rambam Maimonides Med J*. 2011 Apr;2(2):e0049.
- [53] Black CK, Termanini KM, Aguirre O, Hawksworth JS, Sosin M. Solid organ transplantation in the 21st century. *Ann Transl Med*. 2018 Oct;6(20):409–409.
- [54] Volpato V, Webber C. Addressing variability in iPSC-derived models of human disease: guidelines to promote reproducibility. *Disease Models & Mechanisms*. 2020 Jan 1;13(1):dmm042317.
- [55] Lo B, Parham L. Ethical issues in stem cell research. *Endocr Rev*. 2009 May;30(3):204–13.
- [56] Harris AR, Walker MJ, Gilbert F. Ethical and regulatory issues of stem cell-derived 3-dimensional organoid and tissue therapy for personalised regenerative medicine. *BMC Med*. 2022 Dec 27;20(1):499.
- [57] Issa J, Abou Chaar M, Kempisty B, Gasiorowski L, Olszewski R, Mozdziak P, et al. Artificial-Intelligence-Based Imaging Analysis of Stem Cells: A Systematic Scoping Review. *Biology (Basel)*. 2022 Sep 28;11(10):1412.
- [58] Single-cell multi-omics allows functional characterization of structural variants. *Nat Biotechnol*. 2023 Jun;41(6):771–2.
- [59] Srivastava D, DeWitt N. In Vivo Cellular Reprogramming: The Next Generation. *Cell*. 2016 Sep 8;166(6):1386–96.
- [60] Putthanbut N, Lee JY, Borlongan CV. Extracellular vesicle therapy in neurological disorders. *J Biomed Sci*. 2024 Aug 25;31(1):85.
- [61] Ramadan Q, Sharma P. Editorial: Tissue Engineering for Drug Discovery and Personalized Medicine. *Front Med Technol*. 2021 Feb 26;3:663057.